ClinicalTrials.gg
CompletedNCT03770026Updated Apr 29, 2020

Autologous Platelet-rich Plasma for Clomiphene Citrate-induced Thin Endometrium

A Phase 2/3 interventional study of clomiphene citrate and Saline cervical flushing in Infertility, Female, Associated With Anovulation, sponsored by Benha University. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2020-04-29.

Sponsored by Benha University · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jan 2018, registered Dec 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Infertility by Benha University — none open to participants now, none under way, none of them phase 3. Infertility · Benha University.

Enrollment
10th of 11
30 · median 108
Started
2018
the only one that year
Phase 2/3
6 of 13
none open now
Registered
11th of 13
by date

Among the 13 studies in Infertility by Benha University, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 2/3, and was the 11th registered.

Infertility

2,088 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

None of the 13 studies in Infertility by Benha University is open now. The open studies under Infertility, anywhere →

Where they have run

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Infertility by Benha University as a file.
02

Study summary

This is a prospective self-controlled clinical study. Women with clomiphene Citrate failure with thin endometrium less than 7 millimeters for at least 3 cycles will be selected (N = 30). Patients will receive 2 ovarian stimulation cycles with Clomiphene citrate (CC) 100 mg/ day for 5 days from cycle day 3. A control cycle (CC only cycle) woman will continue on CC alone plus cervical irrigation of cervix with 1 ml of 0.9% normal saline at cycle day 8 and 10 to assure patient-blinded method. The study group, the same will be done plus the intrauterine infusion of Autologous platelet-rich plasma (PRP) in 8th and 10th days of the cycle. In both groups, the endometrial thickness and Power Doppler evaluation of their endometrial and sub-endometrial blood flow will be measured on the day of Human Chorionic Gonadotropin (HCG) administration.

Read the detailed description

This is a pilot prospective self-controlled clinical trial. Women with Clomiphene Citrate failure with documented thin endometrium less than 7 millimeters for at least 3 stimulation cycles will be chosen (N = 30). Patients will experience 2 ovarian stimulation cycles with Clomiphene citrate (CC) in a dose of 100 mg/ day for 5 days starting from cycle day 3. A control cycle (CC only cycle) woman will continue on Clomiphene Citrate alone plus cervical irrigation of cervix with 1 ml of 0.9% normal saline at cycle day 8 and 10 to confirm patient-blinded process.

The study group, the same will be done in addition to the intrauterine infusion of with Autologous platelet-rich plasma (PRP) in 8th and 10th days of the cycle.

In both groups, the endometrial thickness and Power Doppler evaluation of their endometrial and sub-endometrial blood flow will be measured on the day of HCG administration.

03

Conditions studied

  • Infertility, Female, Associated With Anovulation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with clomiphene citrate failure (defined as at least previous 3 ovulatory cycles with clomiphene citrate, with no pregnancy),
  • persistently thin endometrium (less than 7 millimeters in at least 3 cycles).
  • normal baseline Follicle Stimulating Hormone, Luteinizing Hormone, and free testosterone levels, patent tubes by hysterosalpingography, and satisfactory male semen analysis

Exclusion criteria

Exclusion Criteria:

  • previous ovarian surgery;
  • endocrine disorders ;
  • pelvic pathologies;
  • chronic hepatic, cardiovascular, or renal disease;
  • other factors of infertility and
  • use of gonadotropins or hormonal through the latest 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Clomiphene citrate only

    Infertile women (30 women) with prior clomiphene citrate failure (ovulation was documented without conception), with thin endometrium (\<7mm) in at least 3 cycles. Saline cervical flushing will be done at cycle day 8 and 10 to convince patient-blinded procedure.

    Drug: clomiphene citrate · Drug: Saline cervical flushing

  • Experimental
    Platelet-rich plasma plus Clomiphene

    Women who did not conceive on the Clomiphene citrate-only cycle will receive Clomiphene citrate 100 mg/ day starting from the third day of the cycle. Intrauterine Autologous platelet-rich plasma will be done on the cycle days 8 and 10.

    Drug: clomiphene citrate · Biological: Intrauterine Autologous platelet-rich plasma

Interventions

  • Clomiphene citrate-only arm: Patients will receive Clomiphene citrate induction (in a dose of 100 mg/day starting from day 3 of the cycle for 5 days). Sonographic assessment of endometrial thickness together with Power Doppler evaluation endometrial and sub-endometrial blood flow a will be done in the Day of HCG injection.

    Also known as: Clomiphene

  • Cervical irrigation with 1 ml of 0.9% normal saline will be done at cycle day 8 and 10 to convince patient-blinded procedure.

    Also known as: Saline

  • Under complete aseptic cares and ultrasound supervision, Autologous platelet-rich plasma (0.5 - 1 ml) was immediately injected into the uterine cavity using an intrauterine insemination catheter in the cycle days 8 and 10. The Autologous platelet-rich plasma is prepared in collaboration with the Department of Clinical Pathology, Faculty of Medicine, Benha University.

    Also known as: Platelet-rich plasma

06

What researchers measure

Primary outcomes

  1. Endometrial thickness

    Transvaginal sonographic estimation of maximal distance traversing endometrial- myometrial interphase on each endometrial stripe in a -midsagittal plane in the uterine fundus.

    Time frame: 1 day

Secondary outcomes

  1. Power Doppler estimation of endometrial and sub-endometrial vascularity

    Endometrial and sub-endometrial vascularity signals will be evaluated using the power Doppler.

    Time frame: 1 day

  2. Clinical pregnancy rate

    Recognizing pregnancy through positive urinary HCG test plus sonographic detection of cardiac pulsations

    Time frame: At the end of a 28-day menstrual cycle.

07

Study locations

1 site
  • Banha Faculty Hospital
    Banha, Alkalubia 13511, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Jan 2019, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2018
First posted
Dec 10, 2018
StartActual
Jan 1, 2018
Primary completionActual
Jan 1, 2019
CompletionActual
Jan 1, 2020
Last update
Apr 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03770026
Lead sponsor
Benha University
Responsible party
Ahmed Walid Anwar Murad (Professor of Obestetrics and Gynecology, Benha University) — Principal investigator
First posted
Dec 10, 2018
Start date
Jan 1, 2018
Primary completion
Jan 1, 2019
Completion
Jan 1, 2020
Last update
Apr 29, 2020

Study contacts

Ahmed Walid A Morad
principal investigator · Banha Faculty of Medicine, Banha Univerisity

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Start the discussion